Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBT Margin (2016 - 2025)

Historic EBT Margin for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to 12.74%.

  • Myriad Genetics' EBT Margin fell 28000.0% to 12.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 51.53%, marking a year-over-year decrease of 373800.0%. This contributed to the annual value of 14.74% for FY2024, which is 200700.0% up from last year.
  • As of Q3 2025, Myriad Genetics' EBT Margin stood at 12.74%, which was down 28000.0% from 155.14% recorded in Q2 2025.
  • Myriad Genetics' 5-year EBT Margin high stood at 23.79% for Q3 2021, and its period low was 155.14% during Q2 2025.
  • Moreover, its 5-year median value for EBT Margin was 17.59% (2024), whereas its average is 26.31%.
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 607600bps in 2021, then crashed by -1375500bps in 2025.
  • Over the past 5 years, Myriad Genetics' EBT Margin (Quarter) stood at 27.05% in 2021, then fell by -8bps to 29.3% in 2022, then soared by 44bps to 16.43% in 2023, then fell by -13bps to 18.57% in 2024, then skyrocketed by 31bps to 12.74% in 2025.
  • Its EBT Margin stands at 12.74% for Q3 2025, versus 155.14% for Q2 2025 and 15.01% for Q1 2025.